Quotes 5-day view Delayed Nasdaq
06/29/2022
06/30/2022
07/01/2022
07/05/2022
07/06/2022
Date
75.45(c)
74.53(c)
77.63(c)
78.46(c)
78.35
Last
2 306 851
3 616 595
1 981 990
2 086 508
2 813 439
Volume
+1.00%
-1.22%
+4.16%
+1.07%
-0.14%
Change
Estimated financial data (e) (USD)
Sales 2022
2 921 M
-
-
Net income 2022
389 M
-
-
Net cash position 2022
486 M
-
-
P/E ratio 2022
79,6x
Yield 2022
-
Sales 2023
3 515 M
-
-
Net income 2023
456 M
-
-
Net cash position 2023
1 518 M
-
-
P/E ratio 2023
67,1x
Yield 2023
-
Capitalization
30 753 M
30 753 M
-
EV / Sales 2022
10,4x
EV / Sales 2023
8,32x
Nbr of Employees
6 300
Free-Float
99,5%
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 75.5% of net sales.
All news about DEXCOM, INC.
News in other languages on DEXCOM, INC.
Analyst Recommendations on DEXCOM, INC.
Wall Street pulls back after last week's rally with inflation in focus
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends DEXCOM, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
16
Last Close Price
78,35 $
Average target price
120,89 $
Spread / Average Target
54,3%
Please enable JavaScript in your browser's settings to use dynamic charts.